Press April 15, 2026 Elion Therapeutics Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection June 17, 2024 Elion Therapeutics Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund December 5, 2023 NIH Research Matters Designing a safer antifungal drug by Sharon Reynolds November 8, 2023 Nature Podcast How to tame a toxic yet life-saving antifungal” by Benjamin Thompson & Nick Petrić Howe with Dr Martin Burke November 8, 2023 Elion Therapeutics Sfunga Therapeutics [now Elion Therapeutics] and Deerfield Management Announce Publication on Novel Antifungal SF001 in Nature
April 15, 2026 Elion Therapeutics Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection
June 17, 2024 Elion Therapeutics Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
November 8, 2023 Nature Podcast How to tame a toxic yet life-saving antifungal” by Benjamin Thompson & Nick Petrić Howe with Dr Martin Burke
November 8, 2023 Elion Therapeutics Sfunga Therapeutics [now Elion Therapeutics] and Deerfield Management Announce Publication on Novel Antifungal SF001 in Nature
